Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia

Omer Kucuk*, Larry Kilton, James L Wade, Richard Blough, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number4
DOIs
StatePublished - Dec 1 2000

Fingerprint

Menogaril
B-Cell Chronic Lymphocytic Leukemia
Multiple Myeloma
Drug Therapy
Anthracyclines
Intravenous Infusions
Sepsis

Keywords

  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Menogaril
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{2c04a83246cf412eae6969f8903c3bc2,
title = "Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia",
abstract = "Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.",
keywords = "Chemotherapy, Chronic lymphocytic leukemia, Menogaril, Multiple myeloma",
author = "Omer Kucuk and Larry Kilton and Wade, {James L} and Richard Blough and {Benson III}, {Al B}",
year = "2000",
month = "12",
day = "1",
doi = "10.1097/00000421-200008000-00014",
language = "English (US)",
volume = "23",
pages = "379--383",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. / Kucuk, Omer; Kilton, Larry; Wade, James L; Blough, Richard; Benson III, Al B.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 4, 01.12.2000, p. 379-383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia

AU - Kucuk, Omer

AU - Kilton, Larry

AU - Wade, James L

AU - Blough, Richard

AU - Benson III, Al B

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.

AB - Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.

KW - Chemotherapy

KW - Chronic lymphocytic leukemia

KW - Menogaril

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0034449050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034449050&partnerID=8YFLogxK

U2 - 10.1097/00000421-200008000-00014

DO - 10.1097/00000421-200008000-00014

M3 - Article

C2 - 10955868

AN - SCOPUS:0034449050

VL - 23

SP - 379

EP - 383

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -